Sangamo and Astellas Announce Capsid License Agreement to Deliver Genomic Medicine for Neurological Diseases

Click here to view

Publications

Enhanced anti-tumor activity by Zinc Finger Repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs
October 16th, 2024
Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease
October 16th, 2024
Potent and selective repression of SCN9A by engineered zinc finger repressors for the treatment of neuropathic pain
September 11th, 2024
Systematic Development of Reprogrammed Modular Integrases Enables Precise Genomic Integration of Large DNA Sequences
May 8th, 2024
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
March 2nd, 2024
Compact zinc finger architecture utilizing toxin-derived cytidine deaminases for highly efficient base editing in human cells
February 22nd, 2024
Feasibility of manufacture of chimeric antigen receptor-regulatory T cells from patients with end-stage renal disease
July 17th, 2023
Resolution of hepatic fibrosis after zinc-finger nuclease-mediated gene editing in the PiZ mouse model of human alpha-1-antitrypsin deficiency liver disease
March 7th, 2023
First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B
November 1st, 2022
Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
October 4th, 2022